urticaria
Conditions
Interventions
treatment group:Acrivastine 8mg, 3 times a day+ Clarityne 10mg, once a day
control group:placebo 8mg, 3 times a day+ Clarityne 10mg, once a day
control group:Acrivastine 8mg, 3 times a day+ placebo 10mg, once a day
Sponsors
Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged from 18-80 years male and female; 2. Clinically Diagnosed with chronic and intractable urticaria; 3. Invalid after taking the Second generation antihistamines for atleast 7 days; 4. Participant fully understands the content of the clinical trial, is willing to attend the research voluntary and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. women in pregnancy and/or lactation; 2. other types of chronic urticaria (including physical urticaria, aquagenic urticaria, cholinergic urticaria, contact urticaria, exercise induced urticaria); 3. accompanied with eczema and atopic dermatitis; 4. known allergic history toward drug or moisturizer under study; 5. Have severe hepatic disease, kidney disease, hematological system diseases, autoimmune disease, chronic severe infectious disease,diabetes, mental illness, drug addiction, alcoholism; 6. There are known pathological arrhythmias and organic heart disease; QT delay is known or suspected; 7. have a history of malignancy or any severe or uncontrolled systemic disease; 8. have taken systemic corticosteroids or other systemic immune inhibitors (e.g. Tripterygium wilfordii et al.) within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DLQI;Patients on the severity of the disease overall grading evaluation;urticaria activity score; | — |
Secondary
| Measure | Time frame |
|---|---|
| pruritus; | — |
Countries
China
Contacts
Public ContactLinfeng Li
Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed